Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania. Show more
The Tannery, Yardley, PA, 19067, United States
Market Cap
1.103B
52 Wk Range
$2.92 - $7.00
Previous Close
$5.37
Open
$5.49
Volume
1,295,972
Day Range
$5.40 - $5.60
Enterprise Value
964.8M
Cash
202.8M
Avg Qtr Burn
-33.05M
Insider Ownership
2.59%
Institutional Own.
-
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MOLBREEVI (Molgramostim) Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | PDUFA Approval decision |